Overview
Compass Pathways Q3 net loss driven by non-cash warrant liabilities adjustment
Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions
Operating income for Q3 beats analyst expectations
Outlook
Company accelerating commercial launch of COMP360 by 9-12 months
COMP360 9-week data from COMP006 expected in Q1 2026
COMP360 26-week data from COMP006 expected in early Q3 2026
Result Drivers
R&D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$1.44 | ||
Q3 Net Income | -$137.71 mln | ||
Q3 Operating Income | Beat | -$40.53 mln | -$42.70 mln (8 Analysts) |
Q3 Operating Expenses | $40.53 mln | ||
Q3 Pretax Profit | -$137.94 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Compass Pathways PLC is $14.00, about 57.5% above its November 3 closing price of $5.95
Press Release: ID:nBw3fCSJha
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)